We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+49.94%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
(+33%)
Cap. Flow
-$3.86M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.2M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$14.5M |
| 3 |
Cytokinetics
CYTK
|
+$13.8M |
| 4 |
Dyne Therapeutics
DYN
|
+$13.8M |
| 5 |
Zai Lab
ZLAB
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HilleVax
HLVX
|
+$21.1M |
| 2 |
CG Oncology
CGON
|
+$20M |
| 3 |
Disc Medicine
IRON
|
+$12.9M |
| 4 |
Cogent Biosciences
COGT
|
+$12.5M |
| 5 |
Travere Therapeutics
TVTX
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
51
DELISTED
HilleVax
HLVX
| – | – |
-10,617,062
| Closed | -$21.1M | – |
|
52
Oric Pharmaceuticals
ORIC
$1.32B
| – | – |
-1,065,334
| Closed | -$10.8M | – |
|
53
Oruka Therapeutics
ORKA
$4.89B
| – | – |
-583,327
| Closed | -$6.54M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2025 Portfolio in Review
As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
- Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
- Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
- Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
- Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
- Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
- Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.